Brainstorm Cell Therapeutics (NASDAQ:BCLI) Announces Quarterly Earnings Results

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04, reports.

Brainstorm Cell Therapeutics Trading Up 1.1%

Shares of BCLI traded up $0.01 during trading hours on Tuesday, reaching $0.96. 28,110 shares of the company traded hands, compared to its average volume of 19,581. The firm has a market cap of $14.22 million, a price-to-earnings ratio of -0.29 and a beta of 0.35. Brainstorm Cell Therapeutics has a 12-month low of $0.46 and a 12-month high of $1.69. The stock’s fifty day moving average price is $0.91 and its 200 day moving average price is $0.86.

Brainstorm Cell Therapeutics Company Profile

(Get Free Report)

BrainStorm Cell Therapeutics is a biotechnology company focused on developing cell therapies for neurodegenerative diseases. Its lead program, NurOwn, is an investigational treatment designed to use a patient’s own bone marrow-derived mesenchymal stem cells, modified to produce neurotrophic factors that may support nerve cells. The company has primarily studied NurOwn for amyotrophic lateral sclerosis (ALS). The therapy has been evaluated in clinical trials, including a Phase 3 study; it is investigational and has not been established as an approved treatment.

Read More

Earnings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.